Accelerate your MedTech innovation with CPI – UK expertise for US companies

Accelerate your MedTech innovation with CPI – UK expertise for US companies

Accelerate your MedTech innovation with CPI – UK expertise for US companies

From breakthrough to market – faster, safer, and smarter.

CPI is an independent deep-tech innovation centre with more than 20 years of experience helping companies bring transformative MedTech solutions to life. We partner with UK, US and Global innovators to develop, prove, scale-up, and commercialise products in patient monitoring, in-vitro diagnostics (IVD), and drug-delivery devices.

Allow YouTube content?

This page contains content provided by YouTube. We ask for your permission before anything is loaded, as they may be using cookies and other technologies for tracking and advertising. You may want to read their cookie policy and privacy policy before accepting. To view this content, choose ‘Accept and continue’.

Why US MedTech companies choose CPI

Speed to market

From defining user needs to full-scale production, CPI’s end-to-end capabilities and $300M in cutting-edge facilities mean you can advance without the delays of building infrastructure.

Speed to market

From defining user needs to full-scale production, CPI’s end-to-end capabilities and $300M in cutting-edge facilities mean you can advance without the delays of building infrastructure.

De-risk your development

Our 500+ scientists and engineers provide multidisciplinary expertise across materials, formulation, digital & software, fabrication, testing, and regulatory; ensuring your product is technically and commercially ready.

De-risk your development

Our 500+ scientists and engineers provide multidisciplinary expertise across materials, formulation, digital & software, fabrication, testing, and regulatory; ensuring your product is technically and commercially ready.

Maximise your investment

Leverage CPI’s facilities, expertise, and UK government backing to reduce capital expenditure, access strategic networks, and secure funding.

Maximise your investment

Leverage CPI’s facilities, expertise, and UK government backing to reduce capital expenditure, access strategic networks, and secure funding.

Regulatory confidence

Navigate FDA, CE, and UKCA requirements with our regulatory specialists, streamlining approval while you focus on innovation.

Regulatory confidence

Navigate FDA, CE, and UKCA requirements with our regulatory specialists, streamlining approval while you focus on innovation.

Our expertise

IVD

From technology definition to scale-up, including assay development, lateral flow, and advanced biosensors.

Patient monitoring

Non-invasive and minimally invasive wearable devices, flexible electronics, and wearable solutions.

Drug delivery devices

Advanced wound healing, drug delivery systems, and novel therapeutic formats.

MedTech regulatory support

Product development with regulatory expertise and guidance for seamless compliance with global healthcare standards.

Proven impact – Real US-relevant success stories

MIT

CPI regularly hosts MIT placement students in its facilities in the UK. They work alongside CPI’s team in medtech, formulations, and biotechnology, providing real impact to the global companies we support.

MIT

CPI regularly hosts MIT placement students in its facilities in the UK. They work alongside CPI’s team in medtech, formulations, and biotechnology, providing real impact to the global companies we support.

Calysta

CPI helped Calysta develop and scale up a gas fermentation process that converts carbon gases into a sustainable protein for aquaculture. CPI advanced from early development to producing tonnes of material at its facilities in the UK.

Calysta

CPI helped Calysta develop and scale up a gas fermentation process that converts carbon gases into a sustainable protein for aquaculture. CPI advanced from early development to producing tonnes of material at its facilities in the UK.

CEPI and Caltech

CPI leads the engineering biology process development of the novel MOSAIC‑8 vaccine, which was developed at Caltech and enables protection against SARS-CoV‑2 variants and other Betacoronaviruses. The vaccine is now in phase I clinical trials.

CEPI and Caltech

CPI leads the engineering biology process development of the novel MOSAIC‑8 vaccine, which was developed at Caltech and enables protection against SARS-CoV‑2 variants and other Betacoronaviruses. The vaccine is now in phase I clinical trials.

Alnylam Labs

Partnering with CPI to develop a manufacturing centre for oligonucleotide therapeutics that use novel manufacturing processes such as liquid phase and enzymatic.

Alnylam Labs

Partnering with CPI to develop a manufacturing centre for oligonucleotide therapeutics that use novel manufacturing processes such as liquid phase and enzymatic.

Why choose CPI?

CPI has also worked with a whole host of US based clients under strict confidentiality with projects relating to IVD, materials, biotechnology and bioengineering broadly across the pharma, medtech and materials sectors. 

Our cross discipline expertise is world renowned and if you’re innovating at the cutting edge of medtech and need support in strategy, product development, prototyping or scale up and want to move more quickly – talk to us and lets see how our capabilities can augment yours. 

Contents

Share

Share

Get in touch with us

Alex Cole

Director of Market Strategy

Get in touch with us

Alex Cole

Director of Market Strategy

Get in touch with us

Alex Cole

Director of Market Strategy